

## EXHIBIT C


**NEURONTIN<sup>®</sup>**  
**(gabapentin)**

***U.S. Market Update***  
***February 2002***

***Nancy Mancini***  
***April 9, 2002***

# AED Market Trends

New Rx Share Trends




In January 2002, Neurontin's NRx share increased to 24.5% from 24.2% in December 2001.


In January 2002, overall TRx volume in the AED market increased by 4% and NRx volume increased by 10% versus December 2001.

Compared to January 2001, overall TRxs and NRxs in the AED market increased 11% and 12%, respectively.

Overall AED NRx Volume



Overall AED TRx Volume




Source: IMS

**NEURONTIN**  
(gabapentin)


In January 2002, Neurontin's NRx share increased to 24.5% from 24.2% in December 2001.

In January 2002, overall TRx volume in the AED market increased by 4% and NRx volume increased by 10% versus December 2001.

Compared to January 2001, overall TRxs and NRxs in the AED market increased 11% and 12%, respectively.




# Neurontin Prescription Overview



Neurontin recorded 1.4MM total Rx in January 2002 (up 5% from December 2001) with 640,000 new Rx (up 11%) and 740,000 refill Rx (unchanged compared to 12/01).


In January 2002, Neurontin's monthly total Rx increased 19% and new Rx increased 15% compared with January 2001.

The 800mg and 600mg tablets accounted for approximately 15% of the new Rx for Neurontin in January 2002.



Source: IMS

Neurontin NRx Share by Strength




**NEURONTIN**  
(gabapentin)

Neurontin recorded 1.4MM total Rx's in January 2002 (up 5% from December 2001) with 640,000 new Rx's (up 11%) and 740,000 refill Rx's (unchanged compared to 12/01).


In January 2002, Neurontin's monthly total Rx's increased 19% and new Rx's increased 15% compared with January 2001.

The 800mg and 600mg tablets accounted for approximately 15% of the new Rx's for Neurontin in January 2002.




# Neurontin NRx and TRx by Physician Specialty

Neurontin NRx Volume by Specialty



Neurontin TRx Volume by Specialty



Source: IMS

**NEURONTIN®**  
(gabapentin)


Compared to January 2001, Neurontin NRx volume in January 2002 increased 25% among PCPs, 13% among anesth/rehab/ortho/rheum specialists, 5% among neurologists and 1% among psychiatrists. Compared to January 2001, Neurontin to Rx volume in 1/02 increased 29% among PCPs, 16% among anesth/rehab/ortho/rheum specialists, 6% among neurologists and 5% among psychiatrists.

PCPs continue to be the leading prescribers of Neurontin, accounting for 33% of new Rx (up 3% from January 2001) and 36% of total Rx (up 3% from January 2001).

Psychiatrists are the next leading prescribers, accounting for 20% of new Rx (down from 23% in January 2001) and 17% of total Rx (down from 19% in January 2001).

The percentage of Neurontin new Rx accounted for by Anesth/rehab/ortho/rheum specialists remained constant at 14% and Neurologists share decreased to 12% (from 13% in January 2001).

Neurontin NRx Share by Specialty




Compared to January 2001, Neurontin NRx volume in January 2002 increased 25% among PCPs, 13% among anesthesiologists/orthopedic/rheumatology specialists, 5% among neurologists and 1% among psychiatrists. Compared to January 2001, Neurontin total Rx volume in 1/02 increased 29% among PCPs, 16% among anesthesiologists/orthopedic/rheumatology specialists, 6% among neurologists and 5% among psychiatrists.

PCPs continue to be the leading prescribers of Neurontin, accounting for 33% of new Rx's (up 3% from January 2001) and 36% of total Rx's (up 3% from January 2001.)


Psychiatrists are the next leading prescribers, accounting for 20% of new Rx's (down from 23% in January 2001) and 17% of total Rx's (down from 19% in January 2001).

The percentage of Neurontin new Rx's accounted for by Anesthesiologists/orthopedic/rheumatology specialists remained constant at 14% and Neurologists share decreased to 12% (from 13% in January 2001).





# Epilepsy Uses in AED Market



These charts present physician-intended drug uses for epilepsy broken out by product.

In 4Q01, the first generation agents account for 60% of drug uses for epilepsy, with phenytoin accounting for 32% of uses, carbamazepine 15% of uses and Depakote/ene/ER 13% of uses.


Neurontin's share of physician epilepsy uses increased to 5% in 4Q01 (from 3% in 4Q00).

Compared to prior year, Lamictal and Keppra share of epilepsy uses remained steady at 4% and 3%, respectively, while Topamax's share of epilepsy uses increased to 4% (from 3%).

Source: Scott-Levin

**NEURONTIN**  
(gabapentin)


Share of Epilepsy Drug Uses by Product



# Concomitant Use in Epilepsy

MAT February 2001/2002

## Drug Uses for Epilepsy



The monotherapy agents, Depakote/ene/ER, phenytoin, carbamazepine and Trileptal, are used alone 56% of the time to treat epilepsy.

Of the adjunctive therapy agents, Lamictal is used as a monotherapy agent 38% of the time and Neuro is used as monotherapy 32% of the time.

Among the adjunctive agents, Lamictal was the most often utilized adjunctive agent over the past year.

Neurontin's uses both as a monotherapy and as an adjunctive therapy have decreased since last year, and 8%, respectively. Lamictal uses as a monotherapy agent increased 55% over prior year, while its use as an adjunctive therapy agent decreased 9% versus last year.

Legend: ■ Mono 2001 ■ Adjunctive 2001 ■ Mono 2002 ■ Adjunctive 2002

MAT 2/02 Share	Depakote/ene/ER	Total Phenytoin	Total carbamazepine	Neurontin	Topamax	Lamictal	Keppra	Zonegran
Used Alone	57.8%	68.1%	60.9%	31.5%	26.1%	37.7%	31.9%	42.0%
Depakote/ene/ER	11.2%	4.5%	10.1%	17.1%	16.2%	12.1%	11.7%	17.8%
Total Phenytoin	12.8%	3.3%	8.7%	29.4%	22.0%	13.7%	10.0%	10.8%
Total carbamazepine	0.2%	0.4%	0.6%	17.1%	17.7%	13.2%	24.7%	13.4%
Trileptal	5.3%	3.7%	4.2%	4.4%	5.8%	5.3%	3.5%	3.4%
Neurontin	3.8%	2.1%	3.3%	3.9%	6.1%	3.7%	5.5%	2.3%
Topamax	2.7%	0.9%	4.5%	4.1%	11.2%	4.4%	11.4%	2.0%
Lamictal	1.7%	0.4%	1.0%	0.7%	0.8%	11.7%	16.3%	16.2%
Keppra						4.9%	1.9%	4.5%
Zonegran								

Source: Scott-Levin

**NEURONTIN**  
(gabapentin)


## Drug Uses for Epilepsy

monotherapy agents, Depakote/ene/ER, phenytoin, carbamazepine and Trileptal, are used alone over the time to treat epilepsy.

adjunctive therapy agents. Lamictal is used as a monotherapy agent 38% of the time and Neurontin as monotherapy 32% of the time.


the adjunctive agents, Lamictal was the most often utilized adjunctive agent over the past year.

tin's uses both as a monotherapy and as an adjunctive therapy have decreased since last year, 23% and, respectively. Lamictal uses as a monotherapy agent increased 55% over prior year, while its use adjunctive therapy agent decreased 9% versus last year.




# Neurontin: Physician Prescribing Behavior

Percent of Physicians Prescribing Neurontin by Specialty



Average # of Neurontin New Rx's/Month Among Prescribers




43% of all neurologists prescribed Neurontin in December 2001 (up from 41% in December 2000).

Psychiatrists are the next leading specialty with 30% prescribing Neurontin in December 2001 (up from 28% in December 2000). 18% of all PCPs prescribed Neurontin in December 2001 (up from 14% in 12/00).


Among Neurontin prescribers, PCPs average number of NRxs increased to 3.2 in December 2001 (up 3% from 12/00), while the average number of NRxs decreased for Neurologists and Psychiatrists by 1% and 6%, respectively over the same period.

Across all prescribers, the average number of Neurontin TRxs was 6.9 of which 4.4 are new prescriptions. Neurologists are the heaviest prescribers averaging 18.7 TRxs and 8.4 NRxs per month.

Average Neurontin NRxs vs. TRxs Among Prescribers (January 2002)





# AED Promotion Summary



Depakote/ene/ER was the most heavily detailed product with 9,000 details December 2001, followed by Topamax and Lamictal (4,000 details, each). Neurontin recorded 2,000 details.


Depakote/ene/ER has the highest share of samples by brand with a 39% share (63,000 samples) in December 2001. Topamax was the next most sample product with a 17% share (27,000 samples). Neurontin recorded 22,000 samples with a 14% share.



**NEURONTIN®**  
(gabapentin)


Depakote/ene/ER was the most heavily detailed product with 9,000 details in December 2001, followed by Topamax and Lamictal (4,000 details, each). Neurontin recorded 2,000 details.

Depakote/ene/ER has the highest share of samples by brand with a 39% share (63,000 samples) in December 2001. Topamax was the next most sampled product with a 17% share (27,000 samples). Neurontin recorded 22,000 samples with a 14% share.



# Neurontin Channels/Method of Payment


Neurontin Channels (% of Dollars)



Source: IMS Monthly Retail and Provider Perspective Dollars Report

86% of Neurontin sales are sold through retail and/or mail order channels.

Method of Payment for Neurontin (% of NRxs)



Source: IMS

The method of payment for Neurontin has remained stable over the past 12 months with third-party payers reimbursing over 72% of Neurontin new Rx's.


**NEURONTIN**  
(gabapentin)



86% of Neurontin sales are sold through retail and/or mail order channels.

The method of payment for Neurontin has remained stable over the past 12 months with third-party payers reimbursing over 72% of Neurontin new Rx's.

# Unique Projected Patient Counts



NDC unique patient-level data indicated that the cumulative number of Neurentin patients was 7.7 million as of December 2001. This number represents a patient who had a prescription filled for Neurentin between January 1996 to December 2001. During the full year 2001, the number of new patients filling a Neurentin Rx was 2.3 million, a 16% increase over 2000.

Source: NDC Physician-Level Data

**NEURONTIN**  
(gabapentin)

Neurontin

Topamax  
Lamictal  
Trileptal  
Kaspa  
Zonegran

Neurontin patients was 7.7 million as of December 2001. This number represents a 26 to December 2001. During the full year 2001, the number of new patients filling a

EPILEPSY MARKET-NRX VOLUME

Epilepsy Market Custom Monthly Data

Date	Neurontin	Dipacote/ enlarER	Total phenytoin	Total carbamazepine	Topamax	Lamictal	Trileptal	Keppra	Zonagran	Gabitril	Falbatol	All Other AEDs	Total
2/00	422	398	270	230	43	41	2	0	0	5	2	2	607
3/00	471	417	285	244	50	44	8	1	0	5	2	2	654
4/00	440	383	261	222	49	41	8	4	0	4	2	2	599
5/00	482	417	293	242	58	44	9	4	0	5	2	2	660
6/00	488	401	274	232	60	44	10	6	1	5	2	2	641
7/00	475	382	265	223	59	42	10	6	1	4	2	2	620
8/00	519	406	277	234	68	46	12	8	2	5	2	2	685
9/00	497	379	261	223	68	44	13	8	2	4	2	2	665
10/00	551	403	269	223	75	47	16	9	3	4	2	2	633
11/00	517	388	257	216	74	45	17	9	3	4	2	2	661
12/00	505	386	256	215	75	46	18	9	3	5	2	2	631
1/01	558	416	275	233	86	50	20	11	4	5	2	2	682
2/01	518	383	250	211	83	47	20	11	4	5	2	2	623
3/01	578	428	274	228	96	53	25	13	5	6	2	2	681
4/01	547	400	257	215	94	50	26	13	5	6	2	2	657
5/01	586	422	266	222	102	52	30	15	7	8	2	2	684
6/01	560	403	251	212	105	51	32	15	7	8	2	2	658
7/01	572	404	259	221	107	53	34	16	8	9	2	2	673
8/01	602	424	268	229	118	57	39	17	9	11	2	2	708
9/01	551	369	244	203	110	52	38	17	9	10	2	2	656
10/01	626	431	264	223	119	59	45	20	11	13	2	2	733
11/01	592	408	253	208	114	56	47	20	11	12	2	2	694
12/01	579	398	250	211	113	59	48	20	12	13	2	2	684
1/02	640	428	271	232	128	65	55	23	13	15	2	2	743
2/02	586	396	243	203	125	60	53	22	13	14	2	2	680

EPILEPSY MARKET-NRX SHARE

Date	Neurontin	Dipacote/ enlarER	Total phenytoin	Total carbamazepine	Topamax	Lamictal	Trileptal	Keppra	Zonagran	Gabitril	Falbatol	All Other AEDs	Total
2/00	21%	19%	13%	11%	2%	2%	0%	0%	0%	0%	0%	30%	100%
3/00	22%	19%	13%	11%	2%	2%	0%	0%	0%	0%	0%	30%	100%
4/00	22%	19%	13%	11%	2%	2%	0%	0%	0%	0%	0%	30%	100%
5/00	22%	19%	13%	11%	3%	2%	0%	0%	0%	0%	0%	30%	100%
6/00	23%	19%	13%	11%	3%	2%	0%	0%	0%	0%	0%	30%	100%
7/00	23%	18%	13%	10%	3%	2%	1%	0%	0%	0%	0%	30%	100%
8/00	23%	18%	12%	10%	3%	2%	1%	0%	0%	0%	0%	30%	100%
9/00	23%	18%	12%	10%	3%	2%	1%	0%	0%	0%	0%	30%	100%
10/00	24%	18%	12%	10%	3%	2%	1%	0%	0%	0%	0%	29%	100%
11/00	24%	18%	12%	10%	3%	2%	1%	0%	0%	0%	0%	29%	100%
12/00	24%	18%	12%	10%	4%	2%	1%	0%	0%	0%	0%	29%	100%
1/01	24%	18%	12%	10%	4%	2%	1%	1%	0%	0%	0%	29%	100%
2/01	24%	18%	11%	10%	4%	2%	1%	1%	0%	0%	0%	29%	100%
3/01	24%	18%	11%	9%	4%	2%	1%	1%	0%	0%	0%	29%	100%
4/01	24%	18%	11%	9%	4%	2%	1%	1%	0%	0%	0%	29%	100%
5/01	24%	17%	11%	9%	5%	2%	1%	1%	0%	0%	0%	29%	100%
6/01	24%	17%	11%	9%	5%	2%	1%	1%	0%	0%	0%	29%	100%
7/01	24%	17%	11%	9%	5%	2%	1%	1%	0%	0%	0%	29%	100%
8/01	24%	17%	11%	9%	5%	2%	2%	1%	0%	0%	0%	29%	100%
9/01	24%	17%	11%	9%	5%	2%	2%	1%	0%	0%	0%	29%	100%
10/01	25%	17%	10%	9%	5%	2%	2%	1%	0%	1%	0%	29%	100%
11/01	24%	17%	10%	9%	5%	2%	2%	1%	0%	0%	0%	29%	100%
12/01	24%	17%	10%	9%	5%	2%	2%	1%	1%	0%	0%	28%	100%
1/02	24%	16%	10%	9%	5%	2%	2%	1%	1%	0%	0%	28%	100%
2/02	24%	16%	10%	9%	5%	2%	2%	1%	0%	1%	0%	28%	100%

Epilepsy Market Custom Monthly Data

TRX VOLUME

Date	Neurontin	Depakote/ ene/ER	Total phenytoin	Total carbamazepine	Topamax	Lamictal	Trileptal	Keppra	Zonagan	Gabaplin	Feltitol	All Over AEDs	Total
2/00	831	827	819	636	85	96	2	0	0	12	7	1154	4471
3/00	923	886	870	677	97	106	9	0	0	13	7	1245	4833
4/00	878	830	817	636	97	102	12	1	0	12	7	1161	4553
5/00	977	902	881	683	112	110	15	5	0	13	8	1266	4972
6/00	978	873	850	690	116	108	18	8	1	12	7	1235	4866
7/00	987	864	857	656	119	108	20	11	2	12	7	1228	4872
8/00	1049	895	871	670	131	113	24	14	3	12	7	1289	5082
9/00	1016	846	827	641	131	110	26	16	4	12	7	1236	4872
10/00	1088	882	862	666	144	117	31	20	6	12	8	1285	5141
11/00	1073	865	840	640	145	115	33	21	7	12	7	1255	5006
12/00	1093	881	848	649	153	119	37	23	8	12	7	1279	5109
1/01	1160	925	876	673	168	124	41	27	9	13	7	1335	5358
2/01	1067	843	792	606	158	114	40	26	9	12	7	1215	4889
3/01	1202	933	870	684	184	130	48	31	11	13	7	1353	5447
4/01	1159	892	833	653	184	125	50	32	12	14	7	1283	5234
5/01	1229	931	861	656	198	132	57	37	14	15	7	1351	5488
6/01	1198	894	828	628	202	129	60	38	15	16	7	1296	5307
7/01	1237	913	848	643	212	135	65	41	17	18	7	1340	5478
8/01	1279	938	857	651	227	140	73	44	19	20	7	1385	5640
9/01	1204	878	801	606	218	133	73	45	20	19	7	1296	5300
10/01	1399	953	864	653	238	146	85	51	23	22	7	1434	5815
11/01	1295	918	830	624	232	144	88	52	24	22	7	1375	5611
12/01	1318	926	841	633	240	152	94	56	26	24	7	1394	5711
1/02	1380	964	857	650	259	159	103	60	28	26	7	1452	5945
2/02	1282	876	774	584	246	146	89	56	28	25	6	1395	5427
Share of previous month	23%	16%	14%	11%	4%	3%	2%	1%	0%	0%	0%	24%	100%
Share of latest month	23%	16%	14%	11%	5%	3%	2%	1%	1%	0%	0%	24%	100%

Neurontin Prescriptions by Month

Feb-01	Mar-01	Apr-01	May-01	Jun-01	Jul-01	Aug-01	Sep-01	Oct-01	Nov-01	Dec-01	Jan-02	Feb-02
518	586	676	676	676	676	676	676	676	676	676	676	676
549	549	549	549	549	549	549	549	549	549	549	549	549
1067	1262	1262	1262	1262	1262	1262	1262	1262	1262	1262	1262	1262

Neurontin NRx by Strength

Feb-01	Mar-01	Apr-01	May-01	Jun-01	Jul-01	Aug-01	Sep-01	Oct-01	Nov-01	Dec-01	Jan-02	Feb-02
24%	24%	23%	24%	24%	23%	24%	24%	24%	24%	23%	23%	23%
52%	52%	52%	52%	52%	51%	51%	51%	51%	51%	51%	51%	51%
12%	12%	12%	11%	11%	11%	11%	11%	11%	11%	11%	11%	11%
9%	9%	9%	9%	9%	9%	9%	9%	9%	9%	9%	9%	9%
4%	4%	4%	4%	4%	4%	4%	4%	4%	4%	4%	4%	4%
100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%

Neurontin TRx by Strength

Feb-01	Mar-01	Apr-01	May-01	Jun-01	Jul-01	Aug-01	Sep-01	Oct-01	Nov-01	Dec-01	Jan-02	Feb-02
231	260	258	268	258	268	277	259	290	278	280	294	268
564	633	609	645	627	644	664	635	693	671	680	710	646
138	153	147	150	148	152	155	143	150	151	154	159	144
90	105	104	112	112	118	124	120	134	133	139	146	136
43	50	49	53	53	56	59	56	63	62	64	69	63
1057	1202	1159	1229	1198	1237	1279	1203	1339	1295	1318	1380	1262

Neurontin NRx by Specialty

Feb-01	Mar-01	Apr-01	May-01	Jun-01	Jul-01	Aug-01	Sep-01	Oct-01	Nov-01	Dec-01	Jan-02	Feb-02
8	9	9	9	9	9	9	9	9	9	9	9	9
59	64	61	65	61	62	65	59	68	64	62	67	62
65	72	68	74	69	71	75	67	77	73	71	79	71
83	93	89	95	91	94	101	92	104	99	97	105	96
102	113	105	111	105	106	109	100	112	105	102	111	101
134	152	147	160	154	158	168	156	176	168	164	182	166
451	503	479	514	489	500	528	483	547	519	508	555	506
2%	2%	2%	2%	2%	2%	2%	2%	2%	2%	2%	2%	2%
13%	13%	13%	13%	12%	12%	12%	12%	12%	12%	12%	12%	12%
14%	14%	14%	14%	14%	14%	14%	14%	14%	14%	14%	14%	14%
18%	18%	18%	18%	19%	19%	19%	19%	19%	19%	19%	19%	19%
22%	22%	22%	22%	21%	21%	21%	21%	21%	21%	21%	21%	21%
30%	30%	31%	31%	31%	32%	32%	32%	32%	32%	32%	33%	33%

Neurontin TRx by Specialty

Feb-01	Mar-01	Apr-01	May-01	Jun-01	Jul-01	Aug-01	Sep-01	Oct-01	Nov-01	Dec-01	Jan-02	Feb-02
14	16	16	17	17	18	19	17	17	17	17	17	162
150	168	161	169	162	167	170	160	176	170	174	177	162

Epilepsy Market Custom Monthly Data													
Anesth/Renals/ Ortho/Rheum	112	126	121	130	124	128	133	123	137	132	133	141	128
Other Others		178	172	183	178	184	193	181	201	195	198	207	188
Psych	169	189	179	188	180	184	187	175	192	184	184	176	188
POP (GP/FD/OIM)	303	343	334	359	354	368	384	364	406	396	404	421	388

Epilepsy Diagnoses Volume by Brand

4Q99	1Q00	2Q00	3Q00	4Q00	1Q01	2Q01	3Q01	4Q01
All Other AEDs	4089	4089	4089	4089	4089	4089	4089	4089
Trileptal	403	472	513	400	411	357	363	370
Total carbamazepine	362	311	28	30	27	40	28	39
Total phenytoin	693	683	377	351	351	310	320	249
Depakote/ene/ER	231	245	257	226	263	287	198	217
Keppra	—	—	17	31	60	49	37	72
Lamictal	76	68	76	74	81	71	73	68
Topamax	29	63	56	52	55	60	41	70
Neurontin	86	120	108	72	83	88	67	74

Epilepsy Diagnoses Share by Brand

4Q99	1Q00	2Q00	3Q00	4Q00	1Q01	2Q01	3Q01	4Q01
All Other AEDs	23%	23%	26%	22%	22%	15%	21%	22%
Trileptal	1%	1%	1%	2%	1%	2%	2%	2%
Total carbamazepine	19%	17%	19%	21%	17%	16%	19%	15%
Total phenytoin	33%	31%	33%	32%	32%	34%	32%	32%
Depakote/ene/ER	12%	13%	11%	10%	10%	15%	12%	13%
Keppra	—	—	2%	2%	3%	2%	4%	3%
Lamictal	4%	4%	4%	4%	4%	4%	4%	4%
Topamax	2%	3%	3%	3%	3%	3%	2%	4%
Neurontin	5%	6%	4%	3%	4%	5%	4%	5%

Concomitant Use in Epilepsy - MAT 2002

Volume	Total phenytoin	carbamazepine	Trileptal	Neurontin	Topamax	Lamictal	Keppra	Zonégren
Mono 2001	496	890	67	127	80	85	34	6
Adjunctive 2001	519	678	89	284	255	306	147	51
Mono 2002	539	718	92	57	57	114	88	38
Adjunctive 2002	489	577	60	285	230	262	204	68

Percent of Physicians Prescribing Neurontin by Specialty

	Mar-00	Apr-00	May-00
Anesth/Rehab/ Ortho/Rheum	10%	10%	11%
Neuro	40%	40%	41%
NP&PAs	0%	0%	0%
Total Others	3%	3%	3%
PCP (GP/FP/DO/IM)	12%	12%	13%
Psych	26%	26%	27%
Average % of Neurontin New Rx/Month Among Prescribers			

Average # of Neurontin New Rx's/Month Among Prescribers

Specialty	Mar-00	Apr-00	May-00	Jun-00	Jul-00	Aug-00	Sep-00	Oct-00	Nov-00	Dec-00	Jan-01	Feb-01	Mar-01	Apr-01	May-01	Jun-01	Jul-01	Aug-01	Sep-01	Oct-01	Nov-01	Dec-01	Jan-02
Anesth/Rehab/Ortho/Rheum	6.9	6.6	6.8	7.1	6.7	7.1	6.8	6.9	6.8	6.9	6.9	6.8	6.8	7.4	7.1	7.4	7.2	7.4	6.8	7.1	6.9	6.9	7.2
Neuro	8.0	8.7	8.9	9.0	8.5	9.2	8.7	8.9	8.7	8.6	8.5	8.3	9.0	9.9	8.9	9.0	8.6	9.0	8.1	8.9	8.4	8.4	8.7
NP&PAs	3.1	3.1	3.0	3.2	3.0	3.2	3.0	3.3	3.2	3.5	3.3	3.2	3.4	3.6	3.3	3.5	3.3	3.4	3.3	3.3	3.1	3.2	3.2
Total Others	2.7	2.7	2.6	2.7	2.6	2.7	2.6	2.6	2.6	2.6	2.5	2.6	2.8	2.8	2.6	2.8	2.7	2.8	2.7	2.7	2.6	2.7	2.7
PCP (GP/FP/DO/IM)	3.0	3.0	3.0	3.1	3.0	3.1	3.1	3.1	3.0	3.1	3.0	3.0	3.3	3.4	3.2	3.4	3.3	3.4	3.2	3.3	3.2	3.2	3.3
Psych	6.8	6.7	6.8	7.0	6.7	7.1	6.8	7.1	7.0	7.1	7.0	6.9	7.6	7.3	7.1	7.2	7.1	7.2	6.5	7.0	6.7	6.7	6.9
Total Prescribers	4.7	4.6	4.6	4.7	4.5	4.7	4.6	4.6	4.5	4.6	4.5	4.5	4.8	4.8	4.6	4.8	4.6	4.7	4.6	4.5	4.5	4.4	4.5

Average Neurontin Nrx vs. TRxs Among Prescribers (Jan-02)

Specialty	NRx's/Month	TRxs/Month
Anesth/Rehab/Ortho/Rheum	7.2	10.4
Neuro	8.7	18.5
NP&PAs	3.2	4.0
Total Others	2.7	3.6
PCP (GP/FP/DO/IM)	3.3	5.2
Psych	6.9	10.0
Total Prescribers	4.5	6.8

Epilepsy Market Custom Monthly Data

Volume	Total phenytoin	carbamazepine	Trileptal	Neurontin	Topamax	Lamictal	Keppra	Zonégren
Mono 2001	496	890	67	127	80	85	34	6
Adjunctive 2001	519	678	89	284	255	306	147	51
Mono 2002	539	718	92	57	57	114	88	38
Adjunctive 2002	489	577	60	285	230	262	204	68

AED Dollars	Avg # Neurontin Trx	Avg # AED Trx	Avg # Neurontin Details	AED Trx	Neurontin Trxs	Physicians	# AED Trx \$000
10	181.22	832	1.5	35,759,149	7,719,014	42,997	\$2,865,445
9	55.66	204	0.1	8,776,717	2,318,921	42,998	\$526,764
8	31.64	109	0.1	4,576,117	1,255,373	42,998	\$273,914
7	19.46	59	0.0	2,534,657	700,055	42,998	\$147,737
6	12.26	31	0.0	1,396,853	377,788	42,998	\$77,690
5	7.98	17	0.0	728,239	203,350	42,998	\$41,747
4	5.28	9	0.0	405,492	115,907	42,998	\$23,190
3	3.54	5	0.0	223,552	67,576	42,998	\$12,611
2	2.24	3	0.0	114,875	35,771	42,998	\$6,273
1	1.30	1	0.0	57,618	18,260	42,997	\$3,213
0	0	-	4.9	0	0	1,740	\$0

EPILEPSY MARKET-JOURNAL

Date	Neurontin	Depakote/ ene/ER	Total phenytoin	Total carbamazepine	Topamax	Lamictal	Tifedipal	Keppra	Zonegran	Gabitril	Total Market
3/00	250	65	6	89	37	19	92	5	0	0	559
4/00	214	102	1	82	60	22	100	5	0	44	683
5/00	169	84	1	66	56	20	92	116	23	38	681
6/00	124	120	2	77	63	22	100	96	47	44	711
7/00	151	13	2	59	49	17	28	80	29	32	473
8/00	104	41	2	37	51	12	31	29	30	18	361
9/00	153	0	4	56	68	13	0	29	15	34	386
10/00	91	0	2	32	34	21	0	29	27	40	304
11/00	112	0	0	26	23	12	0	11	9	30	234
12/00	98	87	0	40	22	12	0	32	17	16	349
1/01	64	83	2	37	31	16	0	18	6	2	265
2/01	63	70	2	45	37	29	0	42	34	2	327
3/01	93	44	2	33	29	14	0	24	13	2	265
4/01	75	0	8	42	51	23	0	45	37	40	328
5/01	70	0	2	32	24	15	0	32	3	31	208
6/01	81	0	2	24	36	21	61	32	8	31	316
7/01	88	0	2	7	25	37	79	32	5	15	289
8/01	93	0	4	19	31	44	80	30	1	16	317
9/01	85	0	10	21	23	51	35	40	0	0	264
10/01	95	11	14	0	34	69	61	44	8	0	336
11/01	104	0	3	3	5	38	31	11	3	0	198
12/01	116	0	4	0	16	14	33	17	4	0	203
1/02	92	0	0	13	19	33	4	39	0	18	269
2/02	61	0	0	6	5	55	8	13	0	17	207
Share of latest month	29%	0%	0%	3%	2%	27%	4%	6%	0%	8%	100%

EPILEPSY MARKET-Details

Date	Neurontin	Depakote/ ene/ER	Total phenytoin	Total carbamazepine	Topamax	Lamictal	Tifedipal	Keppra	Zonegran	Gabitril	All Other AEDs	Total Market
2/00	10	11	-	2	3	2	4	1	-	-	2	35
3/00	10	13	0	2	5	1	6	-	-	1	5	43
4/00	11	11	0	1	3	1	5	1	1	2	1	37
5/00	5	15	-	2	2	2	3	5	2	1	4	41
6/00	12	11	-	1	3	2	5	3	1	1	0	39
7/00	7	13	0	2	3	1	4	2	1	1	1	35
8/00	9	14	-	2	4	2	2	4	1	0	4	42
9/00	6	8	-	1	3	3	3	2	1	1	3	31
10/00	4	6	-	2	5	4	5	3	2	3	3	37
11/00	3	7	0	3	4	3	4	2	2	1	2	31
12/00	2	11	0	2	2	1	3	0	1	0	3	25
1/01	4	16	1	1	5	2	5	1	1	0	2	38
2/01	2	14	0	0	4	2	4	2	1	1	0	30
3/01	2	12	0	2	3	3	4	3	1	3	0	33
4/01	3	12	0	2	4	2	5	1	2	3	2	36
5/01	3	14	0	3	4	3	5	1	3	4	1	41
6/01	2	12	0	3	4	3	3	1	3	2	0	35
7/01	2	14	0	2	5	2	6	3	4	3	3	38
8/01	4	14	0	2	5	2	6	1	3	3	3	43
9/01	4	15	0	2	3	1	4	1	3	3	2	38
10/01	2	18	0	2	3	5	5	1	4	4	2	46
11/01	2	10	0	1	4	2	4	2	4	2	2	33
12/01	2	9	0	1	4	4	3	2	3	1	3	32
1/02	2	13	0	1	6	3	7	2	2	4	9	48
Share of latest month	4%	27%	0%	2%	12%	6%	14%	4%	4%	8%	18%	100%



Date	Neurotin	Dopa/ene/ER	Total phenytoin	Total carbamazepine	Topamax	Lamictal	Trileptal	Keppra	Zonegran	Gabapint	All Other AEDs	Total Market
2/00	47	133	-	-	9	14	152	-	-	-	0	365
3/00	110	240	58	-	9	16	30	30	-	2	12	477
4/00	116	185	13	-	25	6	27	3	-	7	1	385
5/00	33	256	-	-	-	15	35	33	19	3	3	389
6/00	68	84	-	-	9	5	45	19	2	5	1	238
7/00	132	95	-	-	18	-	24	11	13	-	1	284
8/00	174	73	-	5	26	-	-	19	-	-	1	298
9/00	9	71	-	-	11	3	33	14	2	-	0	143
10/00	26	38	-	-	12	7	58	29	14	2	3	190
11/00	13	94	-	40	25	1	33	22	10	-	1	239
12/00	9	115	0	23	3	0	6	-	2	-	-	158
1/01	25	131	2	-	22	-	39	7	6	-	6	238
2/01	36	56	0	0	32	1	26	8	10	2	0	173
3/01	7	87	0	0	6	4	9	18	0	22	0	153
4/01	144	55	-	-	26	-	30	2	9	12	3	281
5/01	7	72	0	8	24	12	27	-	12	32	0	194
6/01	0	73	0	0	31	6	20	0	5	9	0	144
7/01	6	37	2	23	19	2	34	13	17	5	0	137
8/01	142	136	0	0	25	16	80	20	12	12	4	439
9/01	24	122	0	0	44	15	34	4	12	23	0	244
10/01	0	140	0	0	42	0	0	0	16	7	0	222
11/01	7	62	0	0	27	6	10	4	1	26	0	151
12/01	22	63	0	0	36	7	65	9	18	3	0	162
1/02	11	82	0	0	0	7	19	57	16	52	25	351
Share of latest month	3%	23%	0%	0%	10%	2%	19%	16%	5%	15%	7%	100%

Neurotin Channels (% of Dollars)

Neurotin Channels (% of Dollars)	Mar-00	Apr-00	May-00	Jun-00	Jul-00	Aug-00	Sep-00	Oct-00	Nov-00	Dec-00	Jan-01	Feb-01	Mar-01	Apr-01	May-01	Jun-01	Jul-01	Aug-01	Sep-01	Oct-01	Nov-01	Dec-01	Jan-02
Retail Pharmacy	75	74	74	74	74	74	74	73	73	73	72	72	74	73	74	74	74	73	74	73	72	73	72
Mail Order	12	12	12	13	12	12	12	13	12	13	13	13	13	13	13	13	13	13	13	13	14	13	15
LTC	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
Non-Fed Hosp	4	4	3	3	3	3	3	3	4	3	4	3	3	3	3	3	3	3	3	3	3	3	3
Clinics	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
Fed Facilities	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
PHQ	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
All Other	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1

Neurotin Method of Payment

Neurotin Method of Payment	MAT FEB/01	MAT FEB/02
Third Party	71%	72%
Medicaid	17%	17%
Cash	12%	11%

Unique Projected Patient Counts		Zonegran						
		Keppra	Lamictal	Topamax	Triptal	Zonegran		
7/96	240,264		42,081					
8/96	277,198		48,380					
9/96	313,023		50,155					
10/96	355,160		54,779					
11/96	392,858		59,210					
12/96	429,544		63,784					
1/97	469,985		68,575	160				
2/97	511,768		73,782	1,062				
3/97	559,281		78,396	2,864				
4/97	608,322		84,239	5,230				
5/97	657,752		88,422	8,062				
6/97	705,151		93,502	10,875				
7/97	765,716		98,712	13,881				
8/97	818,287		103,382	17,117				
9/97	873,440		108,115	19,538				
10/97	936,141		113,672	22,759				
11/97	992,831		118,704	25,987				
12/97	1,051,506		124,244	28,763				
1/98	1,109,264		128,468	31,408				
2/98	1,170,619		134,250	35,796				
3/98	1,238,723		140,247	38,734				
4/98	1,309,948		146,128	39,656				
5/98	1,382,369		151,901	43,111				
6/98	1,459,404		158,147	46,314				
7/98	1,538,365		164,334	50,024				
8/98	1,620,784		171,044	53,244				
9/98	1,705,337		177,013	56,954				
10/98	1,794,584		183,965	60,354				
11/98	1,885,692		190,745	64,246				
12/98	1,984,858		198,070	68,139				
1/99	2,084,041		205,085	71,709				
2/99	2,191,198		211,938	75,565				
3/99	2,316,413		220,390	80,882				
4/99	2,443,068		228,484	85,781				
5/99	2,565,324		236,856	91,051				
6/99	2,686,864		245,061	97,517				
7/99	2,821,831		253,372	104,734				
8/99	2,966,044		263,034	113,519				
9/99	3,088,251		272,455	123,582				
10/99	3,225,927		281,561	134,172				
11/99	3,360,858		290,503	146,072				
12/99	3,494,350		299,867	158,754				
1/00	3,630,878		306,185	172,418				
2/00	3,779,395		318,896	186,190	1,247			
3/00	3,944,394		328,898	202,967	7,645			
4/00	4,101,150	1,120	338,231	219,536	13,083			
5/00	4,268,673	3,878	347,924	238,777	18,190	246		
6/00	4,437,908	7,853	358,177	259,094	23,769	1,080		
7/00	4,602,498	11,254	368,107	278,232	29,122	2,228		
8/00	4,778,336	15,901	378,416	300,731	35,041	3,643		
9/00	4,945,086	20,195	388,218	323,799	41,020	5,007		
10/00	5,118,133	24,850	398,416	348,094	48,724	6,517		
11/00	5,285,196	29,246	408,200	372,843	56,516	8,103		
12/00	5,447,123	33,226	418,294	397,587	64,460	9,885		
1/01	5,621,652	37,197	428,889	423,870	72,425	11,587		
2/01	5,798,050	41,721	438,987	450,267	80,570	13,452		
3/01	5,977,126	47,434	450,457	482,206	92,018	15,750		
4/01	6,167,712	53,543	467,702	513,201	103,752	18,423		
5/01	6,367,486	60,234	474,339	548,455	117,212	21,985		
6/01	6,558,790	66,917	486,440	585,236	132,546	25,691		
7/01	6,748,475	73,041	498,742	621,321	147,687	29,884		
8/01	6,950,390	79,916	512,523	660,439	163,763	34,454		
9/01	7,132,776	86,202	525,221	695,646	178,836	38,546		
10/01	7,335,685	93,811	539,296	732,066	197,141	43,877		
11/01	7,516,704	100,934	552,836	767,170	214,841	49,876		
12/01	7,705,547	108,421	566,438	804,428	234,352	54,300		
1/02	7,910,208	116,364	581,653	841,710	253,440	59,892		